Frequently Asked Questions

Frequently Asked Questions 

• What impact can I expect this operational consolidation to have on my current program, will there be any changes to established day-to-day interactions?

  There will be no impact on running programs resulting from the operational consolidation of KBI Biopharma, Inc. and Selexis SA.

  Aside from updated email addresses using the @kbibiopharma.com domain, nothing changes in ongoing day-to-day processes. Your main contacts, including business development and/or program management team members, will remain the same throughout the running program.

  Combined email groups will also be maintained, and all emails directed to Selexis email addresses will be automatically re-routed to the new KBI email addresses.

• Will there be any changes to our currently-used Sharepoints?

  All existing data storages have been transferred and carefully tested. If you observe any functionality issues, please inform your program manager as soon as possible so that IT can inspect any potential malfunction. 

• Who do I need to contact going forward?

  Your main contacts are not changing, and you can continue to communicate directly with your business development, program management, and other team members as usual.

  While email addresses have been updated to use the @kbibiopharma.com domain, emails sent to Selexis email addresses will be automatically forwarded. Please update your address book with the new email addresses at your earliest convenience.

• Are standalone services still available?

  While the operational consolidation of KBI and Selexis offers an integrated, streamlined approach that can carry a program from cell line development through to manufacturing, all available service modules - including cell line development, process development, analytical development, formulation development, and manufacturing - continue to remain available as standalone offerings. 

• Do we need to inform our accounting team that invoices may come from a different source?

  The only change you can expect to see here is that the email address from which your team receives the invoice will change to an aligned @kbibiopharma.com domain. All cell line development service invoices will continue to be provided identically to what has been shared in the past. 

• What will happen to our commercial license with Selexis?

  There are no changes to any current CLA, and you can expect to receive the annual letter for milestone updates in the same manner as you have previously received these.